CLYM
Climb Bio Inc4.6200
+0.8100+21.3%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
315.01MP/E (TTM)
-Basic EPS (TTM)
-0.59Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Long-term budoprutug data released
Climb Bio announced long-term follow-up data from its Phase 1b trial of budoprutug, showing sustained proteinuria control for up to three years in four primary membranous nephropathy patients after up to four doses. Three patients needed no further immunosuppression. No grade 3 or higher adverse events occurred. This bolsters budoprutug's potential in B-cell diseases, yet regulatory approvals remain uncertain.
8-K
CLYM116 preclinical data shines
Climb Bio unveiled preclinical data on September 29, 2025, showing its CLYM116 anti-APRIL antibody outperforming sibeprenlimab in nonhuman primates, with ~85% subcutaneous bioavailability, a 2-3 times longer half-life, and >70% maximal IgA reduction after a single 6 mg/kg dose. This positions CLYM116 for less frequent dosing in IgA nephropathy, a $10-20B U.S. market needing lifelong therapies. Phase 1 trial starts Q4 2025. Yet risks like regulatory delays loom.